STELFONTA®
a pharmaceutical treatment for canine mast cell tumours
STELFONTA® (tigilanol tiglate)
Tigilanol tiglate, branded as STELFONTA®*, is approved and marketed as a veterinary pharmaceutical for treatment of non-metastatic, canine mast cell tumours1,2 in the United States of America, European Union, Switzerland, United Kingdom and Australia.
*This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.